368 related articles for article (PubMed ID: 21115550)
1. Development of a preliminary composite disease activity index in psoriatic arthritis.
Mumtaz A; Gallagher P; Kirby B; Waxman R; Coates LC; Veale J D; Helliwell P; FitzGerald O
Ann Rheum Dis; 2011 Feb; 70(2):272-7. PubMed ID: 21115550
[TBL] [Abstract][Full Text] [Related]
2. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
[TBL] [Abstract][Full Text] [Related]
3. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
FitzGerald O; Helliwell P; Mease P; Mumtaz A; Coates L; Pedersen R; Nab H; Molta C
Ann Rheum Dis; 2012 Mar; 71(3):358-62. PubMed ID: 21989542
[TBL] [Abstract][Full Text] [Related]
4. Early psoriatic arthritis.
Gladman DD
Rheum Dis Clin North Am; 2012 May; 38(2):373-86. PubMed ID: 22819090
[TBL] [Abstract][Full Text] [Related]
5. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response.
Helliwell PS; FitzGerald O; Fransen J
J Rheumatol; 2014 Jun; 41(6):1212-7. PubMed ID: 24882854
[TBL] [Abstract][Full Text] [Related]
6. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
Schoels M; Aletaha D; Funovits J; Kavanaugh A; Baker D; Smolen JS
Ann Rheum Dis; 2010 Aug; 69(8):1441-7. PubMed ID: 20525844
[TBL] [Abstract][Full Text] [Related]
7. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI).
Mease PJ
Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S64-85. PubMed ID: 22588772
[No Abstract] [Full Text] [Related]
8. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
9. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
10. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
11. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
12. Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis.
Morgan C; Lunt M; Bunn D; Scott DG; Symmons DP
Rheumatology (Oxford); 2007 Dec; 46(12):1819-23. PubMed ID: 18032539
[TBL] [Abstract][Full Text] [Related]
13. Composite measures in psoriatic arthritis: GRAPPA 2008.
Gladman DD; Landewé R; McHugh NJ; Fitzgerald O; Thaci D; Coates L; Mease PJ; Qureshi AA; Krueger GG; Ritchlin CT; Kavanaugh AF; Garg A
J Rheumatol; 2010 Feb; 37(2):453-61. PubMed ID: 20147481
[TBL] [Abstract][Full Text] [Related]
14. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.
Healy PJ; Helliwell PS
Arthritis Rheum; 2008 May; 59(5):686-91. PubMed ID: 18438903
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
[TBL] [Abstract][Full Text] [Related]
16. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?
Eder L; Chandran V; Shen H; Cook RJ; Gladman DD
Ann Rheum Dis; 2010 Dec; 69(12):2160-4. PubMed ID: 20627946
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab for resistant psoriatic arthritis.
Wallis DE; Waldron NM; Korendowych E
J Rheumatol; 2013 Feb; 40(2):207. PubMed ID: 23378500
[No Abstract] [Full Text] [Related]
18. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response.
Rinaldi F; Provenzano G; Termini A; Spinello M; La Seta F
Ann Rheum Dis; 2005 Sep; 64(9):1375-6. PubMed ID: 16100346
[No Abstract] [Full Text] [Related]
19. Ustekinumab for psoriasis and psoriatic arthritis.
Goldminz AM; Gottlieb AB
J Rheumatol Suppl; 2012 Jul; 89():86-9. PubMed ID: 22751602
[TBL] [Abstract][Full Text] [Related]
20. Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.
Coates LC; Mumtaz A; Helliwell PS; Mease PJ; Callis-Duffin K; Krueger GG; McHugh NJ; Strand V; Gladman DD; FitzGerald O
J Rheumatol; 2011 Jul; 38(7):1496-501. PubMed ID: 21724722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
